Loading...
Market
First biotech company to announce commercial use of bridge RNA-guided DNA recombination by end of 2024?
5
Resolution / Starting Odds
Illumina • 25%
CRISPR Therapeutics • 25%
Editas Medicine • 25%
Intellia Therapeutics • 25%
Press releases from the biotech companies or Arc Institute
Story
Arc Institute's Bridge RNA-Guided DNA Recombination Published in Nature for Precise Genome Editing
Jun 26, 2024, 04:20 PM
Researchers from the Arc Institute have introduced a groundbreaking genome engineering technology known as bridge RNA-guided DNA recombination. This new mechanism, detailed in two papers published in Nature, allows for the programmable insertion, excision, or inversion of DNA sequences. Unlike CRISPR, bridge RNA-guided DNA recombination does not rely on cellular repair mechanisms, potentially making it safer and more precise. The discovery includes three atomic structures of the first natural RNA-guided recombinase, which enhances the power and precision of genome editing for long DNA sequences. This modular system involves the IS110 recombinase and non-coding RNA, significantly reshaping animal and plant genomes.
View original story
Similar markets
Gene therapy • 33%
Agricultural biotechnology • 33%
Synthetic biology • 33%
Wave Life Sciences • 25%
ProQR Therapeutics • 25%
Korro Bio • 25%
Other • 25%
FDA (US) • 25%
EMA (Europe) • 25%
NMPA (China) • 25%
Other • 25%
Yes • 50%
No • 50%
Pfizer • 25%
Roche • 25%
Johnson & Johnson • 25%
Other • 25%
Human gene editing • 25%
Animal models • 25%
Plant genomics • 25%
Microbial engineering • 25%
Pfizer • 25%
Roche • 25%
Novartis • 25%
Other • 25%
Editas Medicine • 25%
Intellia Therapeutics • 25%
CRISPR Therapeutics • 25%
Other • 25%
Pfizer • 25%
Moderna • 25%
Novartis • 25%
Other • 25%
Roche • 25%
Novartis • 25%
Pfizer • 25%
Other • 25%
Wave Life Sciences • 33%
ProQR Therapeutics • 33%
Caribou Biosciences • 33%
Other • 1%
Illumina • 25%
Thermo Fisher Scientific • 25%
Bio-Rad Laboratories • 25%
Other • 25%